Skip to content

Stem cells therapy for patients with acute ischemic stroke.

Intravenous autologous bone marrow derived stem cells therapy for patients with acute ischemic stroke: A multi-institutional project.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2008/091/000046
Enrollment
120
Registered
2008-06-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: intravenous injection of bone marrow mononuclear /stem cells: at a dose of 30 to 500 million Control Intervention1: Standard treatment: Nil

Sponsors

Department of Biotechnology Ministry of Science and Technology Government of India New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Sudden onset of focal neurologic deficit or impairment of consciousness, 2. Computerized tomographic or MRI scan of the head showing no haematoma, and relevant lesions within the MCA and ACA territory. 3. Age between 18 and 70 years 4. Seven days or more but less than 30 days has passed since the onset of the qualifying event, 5. Glasgow Coma Scale score of above 8 at the time of randomization (Appendix 15), in aphasic Eye and Motor score of more than 6, 6. Modified Barthel index score of 50 or less at the time of randomization (Appendix 8). 7. NIHSS score of 7 or more points and inability to walk unaided or raise upper limb by 900 (Appendix 17) 8. Patient is stable: A patient will be defined as stable when he has normal respiration, is afebrile, has BP less than mean arterial pressure of 125mm Hg (but no hypotension defined as systolic BP <90mmHg), has fasting venous blood sugar level less than 200mg% and normal urea/electrolytes for at least 48 hours.

Exclusion criteria

Exclusion criteria: 1. Lacunar syndrome 2. Intubation 3. Posterior Circulation Stroke 4. Co-morbidity likely to limit survival to less than three years e.g. malignant diseases, hepatic or renal failure 5. Pre-stroke disability leading to dependence on others for activities of daily living, 6. Inaccessibility for follow-up 7. Allergy to local anaesthetic 8. Unwillingness to provide written informed consent by self or assent by next of kin. 9. Symptom of Acute myocardial infarction or acute involvement of any other organ. 10. Pregnancy 11. HIV positive. 12. Patient is a part of any other trial.

Design outcomes

Primary

MeasureTime frame
Difference between the two groups in the Modified Barthel index scoreTimepoint: At 180 (-7 to + 28 days) days post-randomisation

Secondary

MeasureTime frame
Functional statusTimepoint: At 180 (-7 to +28 Days) Days and 365 (-7 to +28 Days) Days post-randomization;Modified Rankin scaleTimepoint: At 180 (-7 to + 28 Days) Days and 365 (-7 to +28 Days) Days post-randomisation;NIHSS scoreTimepoint: At 180 (-7 to + 28 Days) Days and 365 (-7 to +28 Days) Days post-randomisation

Countries

India

Contacts

Public ContactKameshwar Prasad
drkameshwarprasad@yahoo.co.in011-26588979

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026